These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1559 related items for PubMed ID: 29042392

  • 1. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA, Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, Lang CC.
    BMJ Open; 2017 Oct 16; 7(10):e018097. PubMed ID: 29042392
    [Abstract] [Full Text] [Related]

  • 2. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC.
    Circulation; 2020 Nov 03; 142(18):1713-1724. PubMed ID: 32865004
    [Abstract] [Full Text] [Related]

  • 3. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    J Am Coll Cardiol; 2021 Mar 23; 77(11):1381-1392. PubMed ID: 33736819
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI.
    Circulation; 2017 Oct 24; 136(17):1643-1658. PubMed ID: 29061576
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K, EMBLEM Trial Investigators.
    Cardiovasc Diabetol; 2017 Apr 12; 16(1):48. PubMed ID: 28403850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
    Brown AJM, Lang C, McCrimmon R, Struthers A.
    BMC Cardiovasc Disord; 2017 Aug 23; 17(1):229. PubMed ID: 28835229
    [Abstract] [Full Text] [Related]

  • 11. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
    Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM.
    Circulation; 2020 Sep 15; 142(11):1028-1039. PubMed ID: 32410463
    [Abstract] [Full Text] [Related]

  • 12. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.
    Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C, EMPA-REG OUTCOME Investigators.
    Clin J Am Soc Nephrol; 2020 Oct 07; 15(10):1433-1444. PubMed ID: 32994159
    [Abstract] [Full Text] [Related]

  • 13. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M.
    Lancet Diabetes Endocrinol; 2021 Feb 07; 9(2):106-116. PubMed ID: 33357505
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M, Butler J.
    Eur J Heart Fail; 2023 Sep 07; 25(9):1537-1543. PubMed ID: 37403655
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, von Eynatten M, Inker LA, Wanner C, Heerspink HJL.
    J Am Heart Assoc; 2020 Sep 15; 9(18):e016976. PubMed ID: 32893717
    [Abstract] [Full Text] [Related]

  • 20. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):274-282. PubMed ID: 32030417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.